RAB30 as A Potential Drug Target for Cancer Treatment (G27314)

Target Name: RAB30

NCBI ID: G27314

RAB30

Other Name(s): RAB30, member RAS oncogene family | RAB30, member RAS oncogene family, transcript variant 2 | RAB30_HUMAN | RAB30 variant 2 | Ras-related protein Rab-30

RAB30 as A Potential Drug Target for Cancer Treatment

RAB30 is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a member of the RAS oncogene family, which is a family of transmembrane proteins that play a crucial role in cell signaling. Activation of the RAS oncogene can lead to the formation of cancerous tumors, and therefore, it is an attractive drug target for researchers. This article will discuss the potential of RAB30 as a drug target or biomarker.

Bioinformatics Analysis

RAB30 is a 21KDa protein composed of a single polypeptide chain. It contains an 伪-helix at the N-terminus, a 尾-curl in the center, and a lysine residue at the C-terminus. RAB30 is expressed in a variety of cancers, including breast, lung, prostate and colon cancer. In normal tissues, the expression level of RAB30 is very low.

RAB30 features

RAB30 is a G protein-coupled receptor (GPCR) that can bind to GPCR ligands in the GPCR signal transduction pathway. GPCR is a signal transduction pathway that controls biological processes such as cell cycle, growth and apoptosis by regulating the concentration of intracellular molecules. RAB30 plays an important role in GPCR signal transduction pathways and is an important component of many signaling pathways.

The relationship between RAB30 and cancer

Studies have shown that RAB30 is expressed in a variety of cancers, including breast, lung, prostate and colon cancer. In breast cancer, the expression level of RAB30 increases with disease progression. In lung cancer, the expression level of RAB30 also increases with disease progression, especially in advanced patients. In prostate cancer and colon cancer, the expression level of RAB30 also increases with disease progression.

Pharmacological significance of RAB30

Because RAB30 is expressed in a variety of cancers, it is considered a potential drug target. Some studies have shown that RAB30 can be used as a drug target to treat various cancers. For example, studies have shown that using inhibitor RNA interference (RNAi) technology can reduce the expression level of RAB30, thereby inhibiting tumor growth. In addition, some drugs, such as gefitinib and cadherin, have also been shown to inhibit the expression level of RAB30, thereby inhibiting tumor growth.

Clinical application

Currently, RAB30 has not been widely used in clinical treatment. Some researchers are exploring RAB30 as a drug target to treat a variety of cancers. For example, some researchers are studying the use of RNAi technology to inhibit the expression levels of RAB30 and test its therapeutic effect on breast, lung, prostate and colon cancer. If the findings are positive, RAB30 could become a potential drug target for treating a variety of cancers.

in conclusion

RAB30 is a protein expressed in a variety of cancers and is considered a potential drug target for many cancers. By inhibiting the expression level of RAB30, tumor growth can be inhibited, thus providing new ideas for the treatment of various cancers. Future research will continue to explore the role of RAB30 in treating cancer and investigate its clinical applications.

Protein Name: RAB30, Member RAS Oncogene Family

Functions: The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (By similarity). Required for maintaining the structural integrity of the Golgi apparatus, possibly by mediating interactions with cytoplasmic scaffolding proteins

The "RAB30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets